Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

[Clinical efficacy of olanzapine].

Yui K.

Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Jul;19(3):101-10. Review. Japanese.

PMID:
10495984
2.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
3.
4.

Olanzapine: an atypical antipsychotic for schizophrenia.

Lund BC, Perry PJ.

Expert Opin Pharmacother. 2000 Jan;1(2):305-23. Review.

PMID:
11249551
5.
6.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.

Am J Psychiatry. 1997 Apr;154(4):457-65.

PMID:
9090331
7.

Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.

Borison RL.

J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):24S-29S. Review.

PMID:
7537285
8.

Efficacy of olanzapine: an overview of pivotal clinical trials.

Beasley CM Jr, Tollefson GD, Tran PV.

J Clin Psychiatry. 1997;58 Suppl 10:7-12.

9.

Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.

Bernardo M, Parellada E, Lomeña F, Catafau AM, Font M, Gómez JC, López-Carrero C, Gutiérrez F, Pavía J, Salamero M.

Psychiatry Res. 2001 Aug 25;107(2):87-97.

PMID:
11530275
10.
11.

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.

Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA.

Psychiatr Serv. 2001 Nov;52(11):1510-4.

PMID:
11684748
13.

Dosing the antipsychotic medication olanzapine.

Nemeroff CB.

J Clin Psychiatry. 1997;58 Suppl 10:45-9.

14.

Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.

Bever KA, Perry PJ.

Am J Health Syst Pharm. 1998 May 15;55(10):1003-16. Review.

PMID:
9606451
15.

In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.

Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brücke T, Kasper S.

Psychopharmacology (Berl). 1999 Jan;141(2):175-81.

PMID:
9952042
16.

Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Foster RH, Goa KL.

Pharmacoeconomics. 1999 Jun;15(6):611-40. Review.

PMID:
10538333
17.

In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.

Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K.

Eur J Nucl Med. 1999 Aug;26(8):862-8.

PMID:
10436199
18.

Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.

Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G, Kikinzon L, Tyano S, Weizman R, Ratzoni G.

J Neural Transm (Vienna). 2003 May;110(5):545-60.

PMID:
12721815
19.

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.

Kapur S, Remington G.

Annu Rev Med. 2001;52:503-17. Review.

PMID:
11160792
20.

Supplemental Content

Support Center